Table 2.
Association between pre-treatment characteristics and sustained virological response - univariate analyses n (%)
| SVR (n = 62) | No-SVR (n = 45) | OR | 95%CI | P | |
| Age, yr (mean ± SD)1 | 47.8 (± 9.1) | 47.1 (± 8.3) | 1 | 0.965-1.055 | 0.696 |
| Male | 61.3 (38) | 77.8 (35) | 0.425 | 0.190-1.079 | 0.093 |
| INFL3 polymorphism CC2 | 31.4 (11) | 24.1 (7) | 1.44 | 0.475-4.372 | 0.585 |
| 3HCV-RNA ≥ 600000 UI/mL | 44.1 (26) | 70.5 (31) | 0.33 | 0.145-0.755 | 0.009 |
| Pre treatment elevated ALT4 | 86.7 (52) | 90.9 (40) | 0.65 | 0.183-2.312 | 0.553 |
| Advanced fibrosis56 | 26.7 (16) | 59.5 (25) | 0.247 | 0.107-0.573 | 0.001 |
| Steatosis | 46.8 (29) | 48.9 (22) | 0.919 | 0.426-1.981 | 0.847 |
| BMI (kg/m2) > 27 | 46.8 (29) | 64.4 (29) | 0.422 | 0.149-0.892 | 0.033 |
| Diabetes | 2 (1) | 11 (5) | 0.131 | 0.015-1.165 | 0.08 |
| Peginterferon alfa 2a | 75.8 (47) | 75.6 (34) | 0.986 | 0.403-2.413 | 1 |
| RBV fix-dose7 | 64.5 (40) | 62.2 (28) | 1.104 | 0.498-2.447 | 0.841 |
| 80/80/80 adherence8 | 95.2 (59) | 93.3 (42) | 0.75 | 0.113-2.552 | 0.919 |
1
Available for 105 patients;
2
Available for 64 patients;
3
Available for 103 patients;
4
Available for 104 patients;
5
Advanced fibrosis includes patients with METAFIR F3 and cirrhosis;
6
Available for 102 patients;
7
800 mg/d;
8
Patients received at least 80% of the peginterferon and RBV doses, and completed at least 80% of the expected treatment duration. ALT: Alanine aminotransferase; HCV: Hepatitis C virus; RBV: Ribavirin; BMI: Body mass index; SVR: Sustained virological response.